IL6 and keratoconus: This is in line with earlier observations of Balasubramanian et al. [30], who paid special attention to the significant increase in IL-6 in patients with KC compared to the CXL-treated group and Kolozsvári et al. [19] who also noted a decrease in IL-6 twelve months after CXL.